Moleculin Biotech
MBRX on Nasdaq. Moleculin Biotech develops Annamycin for people with relapsed or refractory acute myeloid leukemia. Market value $153m.
Price checks use the past 12 months to September 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
Read the warning sign in its own filings
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-276.71 of spare cash last year. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$7.74 a share, 147% above its 1-year low
Over the past year the price has ranged from $3.13 to $106.00.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | n/a | n/a |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.03bn | 0.03bn | 0.00bn | 0.05bn | 0.00bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)2 of 7 checks we could run
- Profit backed by cash (accruals)No
- DebtUnknown
- Revenue growth, five yearsUnknown
- Buying back its own sharesYes, 96% fewer since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $6 million, compared with a loss of $25 million a year ago.
- Sales did not grow on a year ago in any of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | -$7m |
| March 2025 | -$6m |
| June 2025 | -$18m |
| September 2025 | -$25m |
| December 2025 | $15m |
| March 2026 | -$13m |
| June 2026 | -$8m |
| September 2026 | -$6m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 18 March 2026
- Next quarterly (estimated, 10-Q)
- 12 February 2027
Who owns it
None of the long-term investors we follow own it. 18 funds in all.
Largest holders overall
- Geode Capital Management$131,832Added
- Vanguard Capital Management$117,780Added
- Vanguard Fiduciary Trust$83,374Added
- XTX Topco$64,008New
- Morgan Stanley$55,901Added
- Rockefeller Capital Management L.P.$41,850Added
- Tower Research Capital LLC (TRC)$9,804Added
- Citigroup$7,460New
- Barclays$1,733New
- BlackRock$1,370
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
5 investors own more than 5%.
- CVI Investments, Inc.Passive investorat least 9.9%0.0 pts(filed with 1 related holder)Since 30 September 2026
- KLEMP WALTER VInsider or founderat least 9.9%(filed with 1 related holder)Since 19 August 2026
What they said
On August 3, 2026, Mr. Klemp purchased 533,333 shares of Common Stock and Common Warrants to purchase up to 1,599,999 shares of Common Stock for investment purposes. Additional information regarding this transaction is provided above in Item 3. The Reporting Persons reserve the…
Read the filing - Foster Jonathan P.Insider or founder6.3%Since 19 August 2026
What they said
On August 3, 2026, the Reporting Person purchased 293,333 shares of Common Stock and Common Warrants to purchase up to 879,999 shares of Common Stock for investment purposes. Additional information regarding this transaction is provided above in Item 3. The Reporting Person…
Read the filing - Mitchell P. KopinPassive investorat least 5.0%(filed with 2 related holders)Since 31 July 2026
- Armistice Capital, LLCPassive investorat least 5.0%−3.9 pts(filed with 1 related holder)Since 30 June 2025
| Holder | Stake | Since | |
|---|---|---|---|
CVI Investments, Inc. Passive investor | at least 9.9%0.0 pts (filed with 1 related holder) | 30 September 2026 | |
KLEMP WALTER V Insider or founder | at least 9.9% (filed with 1 related holder) | 19 August 2026 | What they saidOn August 3, 2026, Mr. Klemp purchased 533,333 shares of Common Stock and Common Warrants to purchase up to 1,599,999 shares of Common Stock for investment purposes. Additional information regarding this transaction is provided above in Item 3. The Reporting Persons reserve the… Read the filing |
Foster Jonathan P. Insider or founder | 6.3% | 19 August 2026 | What they saidOn August 3, 2026, the Reporting Person purchased 293,333 shares of Common Stock and Common Warrants to purchase up to 879,999 shares of Common Stock for investment purposes. Additional information regarding this transaction is provided above in Item 3. The Reporting Person… Read the filing |
Mitchell P. Kopin Passive investor | at least 5.0% (filed with 2 related holders) | 31 July 2026 | |
Armistice Capital, LLC Passive investor | at least 5.0%−3.9 pts (filed with 1 related holder) | 30 June 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 3 insiders bought $0 of shares on the open market.
- Foster Jonathan P.Chief Financial OfficerBought
- Date
- 3 August 2026
- Shares
- 293,333
- Price
- n/a
- Value
- n/a
- KLEMP WALTER VCEO and President, DirectorBought
- Date
- 3 August 2026
- Shares
- 533,333
- Price
- n/a
- Value
- n/a
- PICKER DONALD HChief Science OfficerBought
- Date
- 3 August 2026
- Shares
- 173,333
- Price
- n/a
- Value
- n/a
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 3 August 2026 | Foster Jonathan P. Chief Financial Officer | Bought | 293,333 | n/a | n/a |
| 3 August 2026 | KLEMP WALTER V CEO and President, Director | Bought | 533,333 | n/a | n/a |
| 3 August 2026 | PICKER DONALD H Chief Science Officer | Bought | 173,333 | n/a | n/a |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Moleculin Biotech’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 18 Mar 2026, plus the 10-Q filed 13 Nov 2026 and 33 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”
Show the full paragraph
Going Concern and Liquidity - These condensed consolidated financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain necessary financing to continue operations and the attainment of profitable operations. As of September 30, 2026 , the Company had an accumulated defici t of $ 233.0 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of $ 7.3 million a s of September 30, 2026 , is not sufficient to fund its planned operations for a period of at least one year from when these condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. These unaudited condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company intends to seek additional funding through one or more of the following: a combination of equity offerings, debt financings, government or other third -party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. There can be no assurance that such events or a combination thereof can be achieved.
From the 10-Q filed 13 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.